Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gary Johnson, M.D.
University of Kansas Medical Center
Principal Investigator - Julia Chapman, M.D.
University of Kansas Medical Center
Principal Investigator - Kathleen Moore, MD
Peggy and Charles Stephenson Oklahoma Cancer Center
Principal InvestigatorKOL profile → - Thomas K Schulz, M.D.
Cancer Center of Kansas
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Kansas Medical Center
Kansas City, Kansas, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
- Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 May 2013
- Completion
- 31 May 2013
- Last update posted
- 27 Feb 2014
- Registered enrollment
- 22
- Registry id
- NCT00666991
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.